Monkeypox (MPX) is a zoonotic disease that is endemic to the western and central regions of Africa and it is caused by monkeypox virus (MPXV), which is classified as a member of the Poxviridae family, specifically the Chordopoxvirinae subfamily, and the Orthopoxvirus genus. The current multiregional outbreak of MPX, which started in May of 2022, has since swiftly spread across the globe and thus has been declared a global public health emergency by the World Health Organization (WHO). Protective immunity against MPXV can be achieved by administering a smallpox vaccination, as the two viruses share antigenic properties. Although smallpox was declared eradicated in 1980, the vaccine campaign was halted the following year, leaving the population with significantly less immunity than it had before. The potential for human-to-human transmission of MPXV has grown as a result. Due to the lack of a particular treatment for MPX infection, anti-viral medications initially designed for the smallpox virus are being employed. However, the prognosis for MPX may vary depending on factors like immunization history, pre-existing illnesses, and comorbidities, even though the majority of persons who develop MPX have a mild, self-limiting illness. Vaccines and antiviral drugs are being researched as potential responses to the latest 2022 MPX epidemic. The first-generation smallpox vaccinations maintained in national stockpiles of several countries are not recommended due to not meeting the current safety and manufacturing criteria, as stated by the WHO. Newer, safer (second- and third-generation) smallpox vaccines, such as JYNNEOSTM, which has been licensed for the prevention of MPX, are indicated as potentially useful in the interim guideline. Studies on vaccines and antiviral drugs are still being investigated as possible remedies to the recent MPX outbreak. This mini-review article serves as a retrospective look at the evolution of smallpox vaccines from their inception in the 1700s to the current trends up to the end of year 2022, specifically for developing monkeypox vaccines.
This research was carried out at the State Museum and Zoo, Thrissur, Kerala, India from June to October, 2009. The objective was to observe and record the physical and behavioural changes in Sambar Deer Rusa unicolor stags linked to their territorial display during various stages of the breeding cycle. In total, there were 70 Sambar in the enclosure, at the commencement of the study, of which 22 were males including 16 adult stags. Six stags were selected for the study. Observations were made by focal animal sampling technique. An ethogram was devised and behavioural patterns were indicated on it. The behavioural score derived from the ethogram was significantly higher in stags in their hard antler stage when compared to the stags in the velvet stage. The stags in the hard antler stage were more massive, had bigger antlers, darker coat colour, thicker neck, larger scrotum and maintained a larger 'harem' in comparison to the velvet stage stags which preferred a rather subdued life. The most dominant stags in the hard antler stage had up to 17 female members in his territory. As the stags in velvet entered the rut season, the dominant stag had up to 19 females in his territory. The study is expected to be useful to evolve strategies to identify and reduce a few males not contributing in breeding in any particular enclosure and thus curtail expenses in management of cervids in captivity.
Recent cases of monkeypox (MPX), a zoonotic illness caused by monkeypox virus (MPXV), outside of Africa have prompted international public health concerns. The emergence, re-emergence, and global dispersion of zoonoses are profoundly impacted by a wide variety of causes, including but not limited to climate change, urbanization, animal migration, quick means of travel and tourism, vector biology, anthropogenic influences, and natural factors. Human MPX was first identified in the Democratic Republic of the Congo (DRC) in 1970, and since then it has spread throughout Africa, particularly to West and Central Africa, with some instances even emerging outside of Africa. Since the 1970s, there has been an increasing trend in the occurrence of human MPX, with the DRC seeing the largest increase. The median age at first presentation has increased from 4 years in the 1970s to 21 years in the current time. The total fatality rate was 8.7%, although there was a significant variation between clades: Central African (10.6%) and West African (3.6%). Since 2003, sporadic outbreaks have occurred outside of Africa due to imports and travel-related dissemination. Risky practices that could lead to contracting MPX include having contact with infected animals or people. There is still much to learn about MPXV, such as the reason for the sudden increase in cases while travel links from endemic countries have not yet been established profoundly, identity the natural reservoir animal(s), make advances in diagnostics, increase surveillance and monitoring, carry out in-depth epidemiological investigations, genome sequencing and phylogenetic analysis, explore the reasons for the changing epidemiology and evolving nature of the virus, its ecological niche, and the discovery of effective treatment and management of MPX. This l mini-review aims to reveal an increase in the number of reported cases of MPX worldwide, with the highest concentration in the DRC, as well as its spread to other countries and a shift in the median age of patients from infants to teenagers and young adults highlighting from older years to current 2022 MPX outbreaks. Some cross-protection against MPX was provided by smallpox vaccination, suggesting that its discontinuation may have contributed to an increase in human-to-human transmission. The disease’s worldwide significance is underscored by the fact that it has spread beyond Africa. As the epidemiology of this resurging disease is constantly shifting, surveillance and detection programs are crucial to keeping up with it.
New research has begun to develop safe and effective alternatives to feed-antibiotics as growth enhancers in response to mounting pressure on the poultry sector to do so. There is a significant demand for poultry products all across the world right now. To achieve this goal, key performance indicators are optimized, such as the rate of chicken growth, the amount of feed used, and the health of the flock as a whole. As a result of this growing need, various alternatives to antibiotics have entered the market. New approaches are desperately needed to keep poultry productivity and efficiency at a high level in the face of mounting pressure to limit the use of antibiotics. Recent years have seen an uptick in interest in the potential of aromatic plant extracts as growth and health boosters in poultry. The great majority of plants' positive effects are accounted for by essential oils (EOs) and other secondary metabolites. EOs have been proven to promote digestive secretion production, improve blood circulation, exert antioxidant qualities, reduce levels of dangerous microbes, and maybe improve the immune status of poultry. EOs are often believed to be safe, non-toxic alternatives because they are all-natural, chemical-free, and devoid of potentially harmful deposits. EOs are extracted from plants, and while there are thousands of them, only approximately 300 have been deemed to have significant commercial value. Many different types of bacteria, viruses, fungi, and parasites are negatively affected by EOs in multiple studies conducted both in vitro and in vivo. The review covers the fundamentals of EOs, their anti-oxidant and immunomodulatory capabilities, their growth-promoting benefits, and their effectiveness against numerous diseases in poultry.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.